Prednisone in lupus nephritis: how much is enough?

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Lupus nephritis management often involves high-dose glucocorticoids, leading to significant toxicity.
• Optimizing treatment protocols for lupus nephritis is crucial for improving patient outcomes and reducing side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel protocol for lupus nephritis utilizing medium-dose prednisone.
• To compare remission rates and glucocorticoid-related toxicity between the novel protocol and a historical high-dose prednisone cohort.

Main Methods:

• A retrospective cohort study comparing the 'Cruces-protocol cohort' (CPC) with medium-dose prednisone and other agents against a 'historic cohort' (HC) on high-dose prednisone.
• Patients were matched 1:2, and outcomes included partial/complete remission rates and glucocorticoid toxicity at 6 and 12 months.

Main Results:

• The CPC (n=15) received significantly lower initial and cumulative prednisone doses compared to the HC (n=30).
• At six months, 80% of CPC patients achieved remission versus 47% in the HC (p=0.015).
• Glucocorticoid toxicity was markedly lower in the CPC (7%) compared to the HC (67%) (p<0.0001).

Conclusions:

• A treatment protocol combining medium-dose prednisone, methylprednisolone pulses, cyclophosphamide, and hydroxychloroquine is effective for lupus nephritis.
• This medium-dose prednisone regimen achieves comparable or better remission rates than high-dose prednisone while significantly reducing toxicity.